1
|
Mardanova ES, Kotlyarov RY, Ravin NV. Rapid Transient Expression of Receptor-Binding Domain of SARS-CoV-2 and the Conserved M2e Peptide of Influenza A Virus Linked to Flagellin in Nicotiana benthamiana Plants Using Self-Replicating Viral Vector. Plants (Basel) 2022; 11:plants11243425. [PMID: 36559537 PMCID: PMC9785242 DOI: 10.3390/plants11243425] [Citation(s) in RCA: 4] [Impact Index Per Article: 2.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/12/2022] [Revised: 11/30/2022] [Accepted: 12/04/2022] [Indexed: 06/12/2023]
Abstract
The development of recombinant vaccines against SARS-CoV-2 and influenza A is an important task. The combination of the conserved influenza A antigen, the extracellular domain of the transmembrane protein M2 (M2e), and the receptor-binding domain of the SARS-CoV-2 spike glycoprotein (RBD) provides the opportunity to develop a bivalent vaccine against these infections. The fusion of antigens with bacterial flagellin, the ligand for Toll-like receptor 5 and potent mucosal adjuvant, may increase the immunogenicity of the candidate vaccines and enable intranasal immunization. In this study, we report the transient expression of RBD alone, RBD coupled with four copies of M2e, and fusions of RBD and RBD-4M2e with flagellin in Nicotiana benthamiana plants using the self-replicating potato virus X-based vector pEff. The yields of purified recombinant proteins per gram of fresh leaf tissue were about 20 µg for RBD, 50-60 µg for RBD-4M2e and the fusion of RBD with flagellin, and about 90 µg for RBD-4M2e fused to flagellin. Targeting to the endoplasmic reticulum enabled the production of glycosylated recombinant proteins comprising RBD. Our results show that plant-produced RBD and RBD-4M2e could be further used for the development of subunit vaccines against COVID-19 and a bivalent vaccine against COVID-19 and influenza A, while flagellin fusions could be used for the development of intranasal vaccines.
Collapse
|
2
|
Mardanova ES, Kotlyarov RY, Ravin NV. High-Yield Production of Receptor Binding Domain of SARS-CoV-2 Linked to Bacterial Flagellin in Plants Using Self-Replicating Viral Vector pEff. Plants (Basel) 2021; 10:plants10122682. [PMID: 34961153 PMCID: PMC8708900 DOI: 10.3390/plants10122682] [Citation(s) in RCA: 10] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/12/2021] [Revised: 11/30/2021] [Accepted: 12/03/2021] [Indexed: 05/07/2023]
Abstract
The development of recombinant vaccines against SARS-CoV-2 is required to eliminate the COVID-19 pandemic. We reported the expression of a recombinant protein Flg-RBD comprising receptor binding domain of SARS-CoV-2 spike glycoprotein (RBD) fused to flagellin of Salmonella typhimurium (Flg), known as mucosal adjuvant, in Nicotiana benthamiana plants. The fusion protein, targeted to the cytosol, was transiently expressed using the self-replicating vector pEff based on potato virus X genome. The recombinant protein Flg-RBD was expressed at the level of about 110-140 μg per gram of fresh leaf tissue and was found to be insoluble. The fusion protein was purified using metal affinity chromatography under denaturing conditions. To increase the yield of Flg-RBD, the flow-through fraction obtained after loading of the protein sample on the Ni-NTA resin was re-loaded on the sorbent. The yield of Flg-RBD after purification reached about 100 μg per gram of fresh leaf tissue and the purified protein remained soluble after dialysis. The control flagellin was expressed in a soluble form and its yield after purification was about 300 μg per gram of fresh leaf biomass. Plant-produced Flg-RBD protein could be further used for the development of intranasal recombinant mucosal vaccines against COVID-19.
Collapse
|
3
|
Zykova AA, Blokhina EA, Kotlyarov RY, Stepanova LA, Tsybalova LM, Kuprianov VV, Ravin NV. Highly Immunogenic Nanoparticles Based on a Fusion Protein Comprising the M2e of Influenza A Virus and a Lipopeptide. Viruses 2020; 12:E1133. [PMID: 33036278 PMCID: PMC7601894 DOI: 10.3390/v12101133] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/27/2020] [Revised: 09/23/2020] [Accepted: 10/01/2020] [Indexed: 12/17/2022] Open
Abstract
The highly conserved extracellular domain of the transmembrane protein M2 (M2e) of the influenza A virus is a promising target for the development of broad-spectrum vaccines. However, M2e is a poor immunogen by itself and must be linked to an appropriate carrier to induce an efficient immune response. In this study, we obtained recombinant mosaic proteins containing tandem copies of M2e fused to a lipopeptide from Neisseria meningitidis surface lipoprotein Ag473 and alpha-helical linkers and analyzed their immunogenicity. Six fusion proteins, comprising four or eight tandem copies of M2e flanked by alpha-helical linkers, lipopeptides, or a combination of both of these elements, were produced in Escherichia coli. The proteins, containing both alpha-helical linkers and lipopeptides at each side of M2e repeats, formed nanosized particles, but no particulate structures were observed in the absence of lipopeptides. Animal study results showed that proteins with lipopeptides induced strong M2e-specific antibody responses in the absence of external adjuvants compared to similar proteins without lipopeptides. Thus, the recombinant M2e-based proteins containing alpha-helical linkers and N. meningitidis lipopeptide sequences at the N- and C-termini of four or eight tandem copies of M2e peptide are promising vaccine candidates.
Collapse
Affiliation(s)
- Anna A. Zykova
- Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, 119071 Moscow, Russia; (A.A.Z.); (E.A.B.); (R.Y.K.)
| | - Elena A. Blokhina
- Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, 119071 Moscow, Russia; (A.A.Z.); (E.A.B.); (R.Y.K.)
| | - Roman Y. Kotlyarov
- Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, 119071 Moscow, Russia; (A.A.Z.); (E.A.B.); (R.Y.K.)
| | - Liudmila A. Stepanova
- Research Institute of Influenza, Russian Ministry of Health, 23805 St. Petersburg, Russia; (L.A.S.); (L.M.T.)
| | - Liudmila M. Tsybalova
- Research Institute of Influenza, Russian Ministry of Health, 23805 St. Petersburg, Russia; (L.A.S.); (L.M.T.)
| | - Victor V. Kuprianov
- Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, 119071 Moscow, Russia; (A.A.Z.); (E.A.B.); (R.Y.K.)
| | - Nikolai V. Ravin
- Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, 119071 Moscow, Russia; (A.A.Z.); (E.A.B.); (R.Y.K.)
| |
Collapse
|
4
|
Tsybalova LM, Stepanova LA, Shuklina MA, Mardanova ES, Kotlyarov RY, Potapchuk MV, Petrov SA, Blokhina EA, Ravin NV. Combination of M2e peptide with stalk HA epitopes of influenza A virus enhances protective properties of recombinant vaccine. PLoS One 2018; 13:e0201429. [PMID: 30138320 PMCID: PMC6107133 DOI: 10.1371/journal.pone.0201429] [Citation(s) in RCA: 16] [Impact Index Per Article: 2.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/16/2018] [Accepted: 07/16/2018] [Indexed: 12/14/2022] Open
Abstract
Background Influenza infection could be more effectively controlled if a multi-purpose vaccine with the ability to induce responses against most, or all, influenza A subtypes could be generated. Conserved viral proteins are a promising basis for the creation of a broadly protective vaccine. In the present study, the immunogenicity and protective properties of three recombinant proteins (vaccine candidates), comprising conserved viral proteins fused with bacterial flagellin, were compared. Methods Balb/c mice were immunized intranasally with recombinant proteins comprising either one viral protein (the ectodomain of the M2 protein, ‘M2e’) or two viral proteins (M2e and the hemagglutinin second subunit ‘HA2’ epitope) genetically fused with flagellin. Further, two different consensus variants of HA2 were used. Therefore, three experimental positives were used in addition to the negative control (Flg-his). The mucosal, humoral, and T-cell immune responses to these constructs were evaluated. Result We have demonstrated that insertion of the HA2 consensus polypeptide (aa 76–130), derived from either the first (HA2-1) or second (HA2-2) virus phylogenetic group, into the recombinant Flg4M2e protein significantly enhanced its immunogenicity and protective properties. Intranasal administration of the vaccine candidates (Flg-HA2-2-4M2e or Flg-HA2-1-4M2e) induced considerable mucosal and systemic responses directed at both the M2e-protein and, in general, the influenza A virus. However, the immune response elicited by the Flg-HA2-1-4M2e protein was weaker than the one generated by Flg-HA2-2-4M2e. These recombinant proteins containing both viral peptides provide complete protection from lethal challenge with various influenza viruses: A/H3N2; A/H2N2; and A/H5N1. Conclusion This study demonstrates that the intranasal administration of Flg-HA2-2-4M2e recombinant protein induces a strong immune response which provides broad protection against various influenza viruses. This construct is therefore a strong candidate for development as a universal vaccine.
Collapse
Affiliation(s)
- Liudmila M. Tsybalova
- Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
- * E-mail:
| | - Liudmila A. Stepanova
- Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - Marina A. Shuklina
- Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - Eugenia S. Mardanova
- Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia
| | - Roman Y. Kotlyarov
- Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia
| | - Marina V. Potapchuk
- Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - Sergei A. Petrov
- Department of Vaccinology, Smorodintsev Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - Elena A. Blokhina
- Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia
| | - Nikolai V. Ravin
- Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Moscow, Russia
| |
Collapse
|
5
|
Koupriyanov VV, Nikolaeva LI, Zykova AA, Makhnovskiy PI, Kotlyarov RY, Vasilyev AV, Ravin NV. IMMUNOGENIC PROPERTIES OF RECOMBINANT MOZAIC PROTEINS BASED ON ANTIGENS NS4A AND NS4B OF HEPATITIS C VIRUS. Vopr Virusol 2018; 63:138-143. [PMID: 36494941 DOI: 10.18821/0507-4088-2018-63-3-138-143] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 01/20/2020] [Indexed: 12/13/2022]
Abstract
The aim of the study was to investigate immunogenic properties of mosaic recombinant proteins constructed on the data of hepatitis C virus NS4A and NS4B antigens. Four mosaic recombinant proteins, containing the T and B epitopes of the NS4A and NS4B antigens, were created by genetic engineering methods in the E. coli system. To enhance the immune response they were linked in different variations to the nucleotide sequences of murine interleukin-2 (IL-2), the Neisseria meningiditis lipopeptide, and the T helper epitope of the core protein of hepatitis C virus. The immunogenic properties of these recombinant proteins were analyzed by immunoblotting, ELISA and ELISpot using sera from immunized mice and patients infected with hepatitis C virus. Recombinant proteins specifically reacted with the sera of immunized mice and infected patients in immunoblotting. According to the ELISA data, the predominant formation of antibodies to NS4B was observed when mice were immunized with the recombinant proteins containing both antigens. Analysis of gamma-interferon production by T-lymphocytes upon contact with activated dendritic cells showed in ELISpot that the maximum production of this cytokine was detected when adjuvant components were located at the N- and C-ends of the recombinant protein. The highest level of gamma-interferon production during stimulation with this drug was detected in lymphocytes from the bone marrow and lymph nodes. The recombinant protein containing the T and B epitopes of NS4A and NS4B, murine IL-2 and the lipopeptide Neisseria meningiditis had the greatest immunostimulate effect among the four constructions. This recombinant protein formed nanoparticles of 100-120 nm in size.
Collapse
Affiliation(s)
| | - L I Nikolaeva
- D.I. Ivanovsky Institute of Virology, «National Research Center for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya»
| | - A A Zykova
- Federal Research Centre «Fundamentals of Biotechnology»
| | - P I Makhnovskiy
- D.I. Ivanovsky Institute of Virology, «National Research Center for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya»
| | - R Y Kotlyarov
- Federal Research Centre «Fundamentals of Biotechnology»
| | - A V Vasilyev
- D.I. Ivanovsky Institute of Virology, «National Research Center for Epidemiology and Microbiology named after the honorary academician N.F. Gamaleya»
| | - N V Ravin
- Federal Research Centre «Fundamentals of Biotechnology»
| |
Collapse
|
6
|
Stepanova LA, Mardanova ES, Shuklina MA, Blokhina EA, Kotlyarov RY, Potapchuk MV, Kovaleva AA, Vidyaeva IG, Korotkov AV, Eletskaya EI, Ravin NV, Tsybalova LM. Flagellin-fused protein targeting M2e and HA2 induces potent humoral and T-cell responses and protects mice against various influenza viruses a subtypes. J Biomed Sci 2018; 25:33. [PMID: 29631629 PMCID: PMC5891888 DOI: 10.1186/s12929-018-0433-5] [Citation(s) in RCA: 27] [Impact Index Per Article: 4.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/13/2017] [Accepted: 03/27/2018] [Indexed: 01/18/2023] Open
Abstract
BACKGROUND Current influenza vaccines are mainly strain-specific and have limited efficacy in preventing new, potentially pandemic, influenza strains. Efficient control of influenza A infection can potentially be achieved through the development of broad-spectrum vaccines based on conserved antigens. A current trend in the design of universal flu vaccines is the construction of recombinant proteins based on combinations of various conserved epitopes of viral proteins (M1, M2, HA2, NP). In this study, we compared the immunogenicity and protective action of two recombinant proteins which feature different designs and which target different antigens. RESULTS Balb/c mice were immunized subcutaneously with Flg-HA2-2-4M2ehs or FlgSh-HA2-2-4M2ehs; these constructs differ in the location of hemagglutinin's HA2-2(76-130) insertion into flagellin (FliC). The humoral and T-cell immune responses to these constructs were evaluated. The simultaneous expression of different M2e and HA2-2(76-130) in recombinant protein form induces a strong M2e-specific IgG response and CD4+/ CD8+ T-cell response. The insertion of HA2-2(76-130) into the hypervariable domain of flagellin greatly increases antigen-specific T-cell response, as evidenced by the formation of multi-cytokine-secreting CD4+, CD8+ T-cells, Tem, and Tcm. Both proteins provide full protection from lethal challenge with A/H3N2 and A/H7N9. CONCLUSION Our results show that highly conserved M2e and HA2-2(76-130) can be used as important targets for the development of universal flu vaccines. The location of the HA2-2(76-130) peptide's insertion into the hypervariable domain of flagellin had a significant effect on the T-cell response to influenza antigens, as seen by forming of multi-cytokine-secreting CD4+ and CD8+ T-cells.
Collapse
Affiliation(s)
- Liudmila A Stepanova
- Research Institute of Influenza, Russian Ministry of Health, Prof. Popova str.15/17, 197376, St. Petersburg, Russia.
| | - Eugenia S Mardanova
- Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Leninsky Ave. 33, building 2, 119071, Moscow, Russia
| | - Marina A Shuklina
- Research Institute of Influenza, Russian Ministry of Health, Prof. Popova str.15/17, 197376, St. Petersburg, Russia
| | - Elena A Blokhina
- Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Leninsky Ave. 33, building 2, 119071, Moscow, Russia
| | - Roman Y Kotlyarov
- Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Leninsky Ave. 33, building 2, 119071, Moscow, Russia
| | - Marina V Potapchuk
- Research Institute of Influenza, Russian Ministry of Health, Prof. Popova str.15/17, 197376, St. Petersburg, Russia
| | - Anna A Kovaleva
- Research Institute of Influenza, Russian Ministry of Health, Prof. Popova str.15/17, 197376, St. Petersburg, Russia
| | - Inna G Vidyaeva
- Research Institute of Influenza, Russian Ministry of Health, Prof. Popova str.15/17, 197376, St. Petersburg, Russia
| | - Alexandr V Korotkov
- Research Institute of Influenza, Russian Ministry of Health, Prof. Popova str.15/17, 197376, St. Petersburg, Russia
| | - Elizaveta I Eletskaya
- Research Institute of Influenza, Russian Ministry of Health, Prof. Popova str.15/17, 197376, St. Petersburg, Russia
| | - Nikolai V Ravin
- Institute of Bioengineering, Research Center of Biotechnology, Russian Academy of Sciences, Leninsky Ave. 33, building 2, 119071, Moscow, Russia
| | - Liudmila M Tsybalova
- Research Institute of Influenza, Russian Ministry of Health, Prof. Popova str.15/17, 197376, St. Petersburg, Russia
| |
Collapse
|
7
|
Mardanova ES, Kotlyarov RY, Kuprianov VV, Stepanova LA, Tsybalova LM, Lomonossoff GP, Ravin NV. High immunogenicity of plant-produced candidate influenza vaccine based on the M2e peptide fused to flagellin. Bioengineered 2015; 7:28-32. [PMID: 26710263 PMCID: PMC4878292 DOI: 10.1080/21655979.2015.1126017] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/06/2015] [Revised: 11/18/2015] [Accepted: 11/23/2015] [Indexed: 10/22/2022] Open
Abstract
The ectodomain of the conserved influenza matrix protein M2 (M2e) is a promising target for the development of a universal influenza vaccines. Immunogenicity of M2e could be enhanced by its fusion to bacterial flagellin, the ligand for Toll-like receptor 5. Previously we reported the transient expression in plants of a recombinant protein Flg-4M comprising flagellin fused to 4 tandem copies of the M2e. The use of self-replicating recombinant vector based on the potato virus X allowed expression of Flg-4M in Nicotiana benthaminana leaves at a very high level, up to about 1 mg/g of fresh leaf tissue. Intranasal immunization of mice with Flg-4M induced M2e-specific serum antibodies and provided protection against lethal challenge with different strains of influenza A virus. Here we show that immunization with Flg-4M not only generates a strong immune response, but also redirects the response from the carrier flagellin toward the M2e epitopes. Significant IgG response to M2e was also developed in bronchoalveolar lavages of immunized mice. Protective activity of Flg-4M upon lethal influenza challenge correlated with a decrease of virus titers in lungs relative to the control. Overall these data show the potential for the development of a plant-produced M2e-flagellin universal influenza vaccine.
Collapse
MESH Headings
- Administration, Intranasal
- Amino Acid Sequence
- Animals
- Antibodies, Viral/biosynthesis
- Epitopes/chemistry
- Epitopes/genetics
- Filaggrin Proteins
- Flagellin/genetics
- Flagellin/immunology
- Genetic Vectors/chemistry
- Genetic Vectors/metabolism
- Humans
- Immunogenicity, Vaccine
- Immunoglobulin G/biosynthesis
- Influenza A Virus, H1N1 Subtype/genetics
- Influenza A Virus, H1N1 Subtype/immunology
- Influenza Vaccines/administration & dosage
- Influenza Vaccines/biosynthesis
- Influenza Vaccines/genetics
- Influenza, Human/immunology
- Influenza, Human/prevention & control
- Influenza, Human/virology
- Mice
- Mice, Inbred BALB C
- Plant Leaves/genetics
- Plant Leaves/metabolism
- Plants, Genetically Modified
- Potexvirus/genetics
- Protein Domains
- Recombinant Fusion Proteins/genetics
- Recombinant Fusion Proteins/immunology
- Nicotiana/genetics
- Nicotiana/metabolism
- Vaccination
- Viral Matrix Proteins/genetics
- Viral Matrix Proteins/immunology
Collapse
Affiliation(s)
- Eugenia S. Mardanova
- Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russia
- Research Institute of Influenza, Russian Federation Ministry of Health, St. Petersburg, Russia
| | - Roman Y. Kotlyarov
- Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russia
- Research Institute of Influenza, Russian Federation Ministry of Health, St. Petersburg, Russia
| | - Victor V. Kuprianov
- Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russia
| | - Liudmila A. Stepanova
- Research Institute of Influenza, Russian Federation Ministry of Health, St. Petersburg, Russia
| | - Liudmila M. Tsybalova
- Research Institute of Influenza, Russian Federation Ministry of Health, St. Petersburg, Russia
| | - George P. Lomonossoff
- Department of Biological Chemistry, John Innes Center, Norwich Research Park, Norwich, UK
| | - Nikolai V. Ravin
- Institute of Bioengineering, Research Center of Biotechnology of the Russian Academy of Sciences, Moscow, Russia
| |
Collapse
|
8
|
Mardanova ES, Kotlyarov RY, Kuprianov VV, Stepanova LA, Tsybalova LM, Lomonosoff GP, Ravin NV. Rapid high-yield expression of a candidate influenza vaccine based on the ectodomain of M2 protein linked to flagellin in plants using viral vectors. BMC Biotechnol 2015; 15:42. [PMID: 26022390 PMCID: PMC4446962 DOI: 10.1186/s12896-015-0164-6] [Citation(s) in RCA: 40] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/20/2015] [Accepted: 05/15/2015] [Indexed: 12/22/2022] Open
Abstract
BACKGROUND The extracellular domain of matrix protein 2 (M2e) of influenza A virus is a promising target for the development of a universal vaccine against influenza because M2e sequences are highly conserved among human influenza A strains. However, native M2e is poorly immunogenic, but its immunogenicity can be increased by delivery in combination with adjuvants or carrier particles. It was previously shown that fusion of M2e to bacterial flagellin, the ligand for Toll-like receptor (TLR) 5 and powerful mucosal adjuvant, significantly increases the immunogenicity and protective capacity of M2e. RESULTS In this study, we report for the first time the transient expression in plants of a recombinant protein Flg-4M comprising flagellin of Salmonella typhimurium fused to four tandem copies of the M2e peptide. The chimeric construct was expressed in Nicotiana benthamiana plants using either the self-replicating potato virus X (PVX) based vector, pA7248AMV-GFP, or the cowpea mosaic virus (CPMV)-derived expression vector, pEAQ-HT. The highest expression level up to 30% of total soluble protein (about 1 mg/g of fresh leaf tissue) was achieved with the PVX-based expression system. Intranasal immunization of mice with purified Flg-4M protein induced high levels of M2e-specific serum antibodies and provided protection against lethal challenge with influenza virus. CONCLUSIONS This study confirms the usefulness of flagellin as a carrier of M2e and its relevance for the production of M2e-based candidate influenza vaccines in plants.
Collapse
Affiliation(s)
- Eugenia S Mardanova
- Centre 'Bioengineering', Russian Academy of Sciences, Prosp. 60-letya Oktyabrya, bld 7-1, 117312, Moscow, Russia.
| | - Roman Y Kotlyarov
- Centre 'Bioengineering', Russian Academy of Sciences, Prosp. 60-letya Oktyabrya, bld 7-1, 117312, Moscow, Russia.
| | - Victor V Kuprianov
- Centre 'Bioengineering', Russian Academy of Sciences, Prosp. 60-letya Oktyabrya, bld 7-1, 117312, Moscow, Russia.
| | - Liudmila A Stepanova
- Research Institute of Influenza, Russian Federation Ministry of Health, 15/17 Prof. Popova str., 197376, St. Petersburg, Russia.
| | - Liudmila M Tsybalova
- Research Institute of Influenza, Russian Federation Ministry of Health, 15/17 Prof. Popova str., 197376, St. Petersburg, Russia.
| | - George P Lomonosoff
- Department of Biological Chemistry, John Innes Centre, Norwich Research Park, NR4 7UH, Norwich, UK.
| | - Nikolai V Ravin
- Centre 'Bioengineering', Russian Academy of Sciences, Prosp. 60-letya Oktyabrya, bld 7-1, 117312, Moscow, Russia.
| |
Collapse
|
9
|
Stepanova LA, Kotlyarov RY, Kovaleva AA, Potapchuk MV, Korotkov AV, Sergeeva MV, Kasianenko MA, Kuprianov VV, Ravin NV, Tsybalova LM, Skryabin KG, Kiselev OI. Protection against multiple influenza A virus strains induced by candidate recombinant vaccine based on heterologous M2e peptides linked to flagellin. PLoS One 2015; 10:e0119520. [PMID: 25799221 PMCID: PMC4370815 DOI: 10.1371/journal.pone.0119520] [Citation(s) in RCA: 39] [Impact Index Per Article: 4.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/18/2014] [Accepted: 01/29/2015] [Indexed: 02/02/2023] Open
Abstract
Matrix 2 protein ectodomain (M2e) is considered a promising candidate for a broadly protective influenza vaccine. M2e-based vaccines against human influenza A provide only partial protection against avian influenza viruses because of differences in the M2e sequences. In this work, we evaluated the possibility of obtaining equal protection and immune response by using recombinant protein on the basis of flagellin as a carrier of the M2e peptides of human and avian influenza A viruses. Recombinant protein was generated by the fusion of two tandem copies of consensus M2e sequence from human influenza A and two copies of M2e from avian A/H5N1 viruses to flagellin (Flg-2M2eh2M2ek). Intranasal immunisation of Balb/c mice with recombinant protein significantly elicited anti-M2e IgG in serum, IgG and sIgA in BAL. Antibodies induced by the fusion protein Flg-2M2eh2M2ek bound efficiently to synthetic peptides corresponding to the human consensus M2e sequence as well as to the M2e sequence of A/Chicken/Kurgan/05/05 RG (H5N1) and recognised native M2e epitopes exposed on the surface of the MDCK cells infected with A/PR/8/34 (H1N1) and A/Chicken/Kurgan/05/05 RG (H5N1) to an equal degree. Immunisation led to both anti-M2e IgG1 and IgG2a response with IgG1 prevalence. We observed a significant intracellular production of IL-4, but not IFN-γ, by CD4+ T-cells in spleen of mice following immunisation with Flg-2M2eh2M2ek. Immunisation with the Flg-2M2eh2M2ek fusion protein provided similar protection from lethal challenge with human influenza A viruses (H1N1, H3N2) and avian influenza virus (H5N1). Immunised mice experienced significantly less weight loss and decreased lung viral titres compared to control mice. The data obtained show the potential for the development of an M2e-flagellin candidate influenza vaccine with broad spectrum protection against influenza A viruses of various origins.
Collapse
Affiliation(s)
- Liudmila A. Stepanova
- Department of Influenza Vaccines, Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
- * E-mail:
| | | | - Anna A. Kovaleva
- Department of Influenza Vaccines, Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - Marina V. Potapchuk
- Department of Influenza Vaccines, Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - Alexandr V. Korotkov
- Department of Influenza Vaccines, Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - Mariia V. Sergeeva
- Department of Influenza Vaccines, Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | - Marina A. Kasianenko
- Department of Influenza Vaccines, Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | | | - Nikolai V. Ravin
- Centre “Bioengineering”, Russian Academy of Sciences, Moscow, Russia
- GenNanotech Ltd, St. Petersburg, Russia
| | - Liudmila M. Tsybalova
- Department of Influenza Vaccines, Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| | | | - Oleg I. Kiselev
- Department of Influenza Vaccines, Research Institute of Influenza, Ministry of Health of the Russian Federation, St. Petersburg, Russia
| |
Collapse
|
10
|
Ravin NV, Kotlyarov RY, Mardanova ES, Kuprianov VV, Migunov AI, Stepanova LA, Tsybalova LM, Kiselev OI, Skryabin KG. Plant-produced recombinant influenza vaccine based on virus-like HBc particles carrying an extracellular domain of M2 protein. Biochemistry (Mosc) 2012; 77:33-40. [PMID: 22339631 DOI: 10.1134/s000629791201004x] [Citation(s) in RCA: 36] [Impact Index Per Article: 3.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/23/2022]
Abstract
Conventional influenza vaccines are based on a virus obtained in chicken embryos or its components. The high variability of the surface proteins of influenza virus, hemagglutinin and neuraminidase, requires strain-specific vaccines matching the antigenic specificity of newly emerging virus strains to be developed. A recombinant vaccine based on a highly conservative influenza virus protein M2 fused to a nanosized carrier particle can be an attractive alternative to traditional vaccines. We have constructed a recombinant viral vector based on potato X virus that provides for expression in the Nicotiana benthamiana plants of a hybrid protein M2eHBc consisting of an extracellular domain of influenza virus M2 protein (M2e) fused to hepatitis B core antigen (HBc). This vector was introduced into plant cells by infiltrating leaves with agrobacteria carrying the viral vector. The hybrid protein M2eHBc was synthesized in the infected N. benthamiana plants in an amount reaching 1-2% of the total soluble protein and formed virus-like particles with the M2e peptide presented on the surface. Methods of isolation and purification of M2eHBc particles from plant producers were elaborated. Experiments on mice have shown a high immunogenicity of the plant-produced M2eHBc particles and their protective effect against lethal influenza challenge. The developed transient expression system can be used for production of M2e-based candidate influenza vaccine in plants.
Collapse
Affiliation(s)
- N V Ravin
- Centre "Bioengineering", Russian Academy of Sciences, Moscow, Russia.
| | | | | | | | | | | | | | | | | |
Collapse
|
11
|
Kotlyarov RY, Kuprianov VV, Migunov AI, Stepanova LA, Tsybalova LM, Kiselev OI, Ravin NV, Skryabin KG. Development of Recombinant Vaccine against A(H1N1) 2009 Influenza Based on Virus-like Nanoparticles Carrying the Extracellular Domain of M2 Protein. Acta Naturae 2010. [DOI: 10.32607/20758251-2010-2-2-71-76] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
|